Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, W. A.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, W. A.
Right arrow Articles by Schwaiger, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 14 (July), 2003: 2651-2657
© 2003 American Society for Clinical Oncology

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Wolfgang A. Weber, Volker Petersen, Burkhard Schmidt, Leishia Tyndale-Hines, Thomas Link, Christian Peschel, Markus Schwaiger

From the Departments of Nuclear Medicine, Internal Medicine III, and Radiology, Technische Universität München, München, Germany.

Address reprint requests to Wolfgang A. Weber, MD, Nuklearmedizinische Klinik, Klinikum Rechts der Isar, Ismaning Straße 22, 81675 München, Germany; email: w.weber{at}lrz.tum.de.

Purpose: To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).

Patients and Methods: Patients with stage IIIB or IV NSCLC scheduled to undergo platinum-based chemotherapy were eligible for this study. Patients were studied by FDG-PET before and after the first cycle of therapy. Based on previous studies, a reduction of tumor FDG uptake by more than 20% as assessed by standardized uptake values (SUV) was used as a criterion for a metabolic response. Furthermore, changes in tumor SUVs were compared with changes in FDG net-influx constants (Ki) and tumor/muscle ratios (t/m).

Results: Fifty-seven patients were included in the study. There was a close correlation between metabolic response and best response to therapy according to Response Evaluation Criteria in Solid Tumors (P < .0001; sensitivity and specificity for prediction of best response, 95% and 74%, respectively). Median time to progression and overall survival were significantly longer for metabolic responders than for metabolic nonresponders (163 v 54 days and 252 days v 151 days, respectively). Similar results were obtained when Ki was used to assess tumor glucose use, whereas changes in t/m showed considerable overlap between responding and nonresponding tumors.

Conclusion: In NSCLC, reduction of metabolic activity after one cycle of chemotherapy is closely correlated with final outcome of therapy. Using metabolic response as an end point may shorten the duration of phase II studies evaluating new cytotoxic drugs and may decrease the morbidity and costs of therapy in nonresponding patients.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
H. A. Jacene, S. Leboulleux, S. Baba, D. Chatzifotiadis, B. Goudarzi, O. Teytelbaum, K. M. Horton, I. Kamel, K. J. Macura, H.-L. Tsai, et al.
Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy
J. Nucl. Med., November 1, 2009; 50(11): 1760 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al.
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Blood, September 3, 2009; 114(10): 2068 - 2076.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Bystrom, A. Berglund, U. Garske, H. Jacobsson, A. Sundin, P. Nygren, J.-E. Frodin, and B. Glimelius
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Ann. Onc., June 1, 2009; 20(6): 1057 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Assessing Tumor Response to Therapy
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Hicks
Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 31S - 42S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Avril, S. Sassen, and R. Roylance
Response to Therapy in Breast Cancer
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. J. Erasmus, E. Rohren, and S. G. Swisher
Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging
Proceedings of the ATS, April 15, 2009; 6(2): 171 - 179.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist, April 1, 2009; 14(4): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. E. Laing, M. A. Walter, D. O. Campbell, H. R. Herschman, N. Satyamurthy, M. E. Phelps, J. Czernin, O. N. Witte, and C. G. Radu
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography
PNAS, February 24, 2009; 106(8): 2847 - 2852.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al.
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Ben-Haim and P. Ell
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
J. Nucl. Med., January 1, 2009; 50(1): 88 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. A. Weber
The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 474 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Holdenrieder, J. von Pawel, E. Dankelmann, T. Duell, B. Faderl, A. Markus, M. Siakavara, H. Wagner, K. Feldmann, H. Hoffmann, et al.
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7813 - 7821.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, S. J. Oh, K. C. Im, D. H. Moon, D. H. Lee, C. Suh, J.-S. Lee, and S.-W. Kim
[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
Clin. Cancer Res., November 15, 2008; 14(22): 7423 - 7429.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Tanvetyanon, E. A. Eikman, E. Sommers, L. Robinson, D. Boulware, and G. Bepler
Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2008; 26(28): 4610 - 4616.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Evilevitch, W. A. Weber, W. D. Tap, M. Allen-Auerbach, K. Chow, S. D. Nelson, F. R. Eilber, J. J. Eckardt, R. M. Elashoff, M. E. Phelps, et al.
Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas
Clin. Cancer Res., February 1, 2008; 14(3): 715 - 720.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott
The expanding role of PET technology in the management of patients with colorectal cancer
Ann. Onc., November 1, 2007; 18(11): 1774 - 1781.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. S. Herbst, A. M. Davies, R. B. Natale, T. P. Dang, J. H. Schiller, L. L. Garland, V. A. Miller, D. Mendelson, A. D. Van den Abbeele, Y. Melenevsky, et al.
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non Small Cell Lung Cancer
Clin. Cancer Res., October 15, 2007; 13(20): 6175 - 6181.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L.-F. de Geus-Oei, H. F.M. van der Heijden, E. P. Visser, R. Hermsen, B. A. van Hoorn, J. N.H. Timmer-Bonte, A. T. Willemsen, J. Pruim, F. H.M. Corstens, P. F.M. Krabbe, et al.
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
J. Nucl. Med., October 1, 2007; 48(10): 1592 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence
A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3116 - 3123.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend
Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
J. Nucl. Med., May 1, 2007; 48(5): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ott, W. A. Weber, F. Lordick, K. Becker, R. Busch, K. Herrmann, H. Wieder, U. Fink, M. Schwaiger, and J.-R. Siewert
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
J. Clin. Oncol., October 10, 2006; 24(29): 4692 - 4698.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Su, C. Bodenstein, R. A. Dumont, Y. Seimbille, S. Dubinett, M. E. Phelps, H. Herschman, J. Czernin, and W. Weber
Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors.
Clin. Cancer Res., October 1, 2006; 12(19): 5659 - 5667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L.-F. de Geus-Oei, E. P. Visser, P. F.M. Krabbe, B. A. van Hoorn, E. B. Koenders, A. T. Willemsen, J. Pruim, F. H.M. Corstens, and W. J.G. Oyen
Comparison of Image-Derived and Arterial Input Functions for Estimating the Rate of Glucose Metabolism in Therapy-Monitoring 18F-FDG PET Studies
J. Nucl. Med., June 1, 2006; 47(6): 945 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, T. Pan, D. D. Cody, R. Campbell, A. H. Lonn, S. Kohlmyer, H. A. Macapinlac, and D. A. Podoloff
Truncation Artifact on PET/CT: Impact on Measurements of Activity Concentration and Assessment of a Correction Algorithm.
Am. J. Roentgenol., May 1, 2006; 186(5): 1458 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard
Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer
J. Nucl. Med., April 1, 2006; 47(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]

Home page
 NEJMHome page
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507.
[Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. L. Chen and F. Dehdashti
Advances in Positron Emission Tomographic Imaging of Lung Cancer
Proceedings of the ATS, December 1, 2005; 2(6): 541 - 544.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart
Imaging of the Patient with Non-Small Cell Lung Cancer
Radiology, December 1, 2005; 237(3): 803 - 818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8362 - 8370.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. K. Shankar and D. C. Sullivan
Functional Imaging in Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3203 - 3211.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Waldherr, I. K. Mellinghoff, C. Tran, B. S. Halpern, N. Rozengurt, A. Safaei, W. A. Weber, D. Stout, N. Satyamurthy, J. Barrio, et al.
Monitoring Antiproliferative Responses to Kinase Inhibitor Therapy in Mice with 3'-Deoxy-3'-18F-Fluorothymidine PET
J. Nucl. Med., January 1, 2005; 46(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio, A. S. Bryant, T. S. Winokur, B. Ohja, and A. A. Bartolucci
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
Ann. Thorac. Surg., December 1, 2004; 78(6): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste
The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Oncologist, November 1, 2004; 9(6): 633 - 643.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online